Published in Gastroenterol Res Pract on February 03, 2016
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int (2017) 0.77
TFCP2 Genetic Polymorphism Is Associated with Predisposition to and Transplant Prognosis of Hepatocellular Carcinoma. Gastroenterol Res Pract (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 16.93
Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis (1999) 12.31
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol (2009) 9.84
Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer (1985) 7.67
Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology (1999) 5.64
The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol (2006) 4.17
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect (2010) 3.35
Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol (2006) 3.09
The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis (2011) 2.96
Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol (2013) 2.89
Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol (2011) 2.74
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol (2010) 2.51
Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol (2009) 2.41
Epidemiology of hepatitis C virus infection in Pakistan. J Microbiol Immunol Infect (2008) 2.28
The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol (2004) 2.18
Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg (2002) 2.14
Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. Int J Infect Dis (2008) 2.13
Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol (2002) 1.88
Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med (2010) 1.86
Karachi Cancer Registry Data--implications for the National Cancer Control Program of Pakistan. Asian Pac J Cancer Prev (2004) 1.85
Cancer control activities in the Republic of Korea. Jpn J Clin Oncol (2008) 1.75
Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology (1985) 1.73
Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology (1992) 1.72
The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. Eur J Cancer (2008) 1.71
Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer (2011) 1.69
Obesity and mortality. N Engl J Med (2005) 1.65
A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology (2010) 1.64
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int (2015) 1.59
Cancer incidence in Karachi, Pakistan: first results from Karachi Cancer Registry. Int J Cancer (2000) 1.55
Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival. J Natl Med Assoc (2006) 1.52
Pakistan's health system: performance and prospects after the 18th Constitutional Amendment. Lancet (2013) 1.47
Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen (1999) 1.41
Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience. World J Gastroenterol (2009) 1.31
Awareness among barbers about health hazards associated with their profession. J Ayub Med Coll Abbottabad (2009) 1.23
Attributable causes of liver cancer mortality and incidence in china. Asian Pac J Cancer Prev (2013) 1.17
Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver Cancer (2013) 1.05
Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. Clinics (Sao Paulo) (2010) 1.05
Impact of new hepatitis C treatments in different regions of the world. Gastroenterology (2014) 1.01
Liver Cancer Working Group report. Jpn J Clin Oncol (2010) 1.00
Hepatocellular carcinoma: A comprehensive review. World J Hepatol (2015) 0.98
Epidemic spread of hepatitis C virus genotype 3a and relation to high incidence of hepatocellular carcinoma in Pakistan. J Med Virol (2009) 0.97
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. Expert Opin Pharmacother (2015) 0.95
Health reform in Pakistan: a call to action. Lancet (2013) 0.95
Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. Eur J Gastroenterol Hepatol (2013) 0.93
Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol Int (2009) 0.92
Hepatocellular carcinoma in Pakistan. J Coll Physicians Surg Pak (2013) 0.91
Prevalence, knowledge and awareness of hepatitis C among residents of three Union Councils in Mansehra. J Ayub Med Coll Abbottabad (2012) 0.90
Lessons learned from a community based intervention to improve injection safety in Pakistan. BMC Res Notes (2013) 0.87
Spectrum of hepatocellular carcinoma at Shifa International Hospital, Islamabad. J Ayub Med Coll Abbottabad (2004) 0.86
Cancer profile of Hyderabad, Pakistan 1998-2002. Asian Pac J Cancer Prev (2006) 0.85
Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2008) 0.85
Hepatocellular carcinoma (HCC) and diagnostic significance of A-fetoprotein (AFP). J Ayub Med Coll Abbottabad (2010) 0.85
Hepatocellular carcinoma: analysis of 76 cases. J Pak Med Assoc (1998) 0.84
Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology. J Pak Med Assoc (2008) 0.84
Barriers to the successful practice of chronic kidney diseases at the primary health care level; a systematic review. J Renal Inj Prev (2014) 0.83
Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? Expert Opin Ther Targets (2015) 0.83
Cancer patterns in Quetta (1998-1999). J Pak Med Assoc (2002) 0.83
Hepatocellular carcinoma in pakistan: where do we stand? Hepat Mon (2012) 0.83
Hepatocellular carcinoma in Native South Asian Pakistani population; trends, clinico-pathological characteristics & differences in viral marker negative & viral-hepatocellular carcinoma. BMC Res Notes (2013) 0.81
Assessment of hot peppers for aflatoxin and mold proliferation during storage. J Food Prot (2011) 0.81
Systemic therapies for hepatocellular carcinoma. Drug Discov Ther (2015) 0.80
Treatment outcomes with long acting octreotide in inoperable hepatocellular carcinoma: a local experience and review of literature. J Pak Med Assoc (2005) 0.79
Prevalence and mode of spread of hepatitis B and C in rural Sindh, Pakistan. Trop Gastroenterol (2009) 0.79
Survival from hepatocellular carcinoma at a cancer hospital in Pakistan. Asian Pac J Cancer Prev (2007) 0.79
Cancer profile of Larkana, Pakistan (2000-2002). Asian Pac J Cancer Prev (2007) 0.79
The travails of setting up a living donor liver transplant program: Experience from Pakistan and lessons learned. Liver Transpl (2015) 0.77
Quality of Life After Living Donor Hepatectomy for Liver Transplantation. World J Surg (2015) 0.77
Aflatoxin and liver cancer in Karachi, a preliminary survey. J Pak Med Assoc (1977) 0.77
A prospective phase II trial to evaluate the efficacy and toxicity of hepatic arterial infusion of ifosfamide in patients with inoperable localized hepatocellular carcinoma. Am J Clin Oncol (1997) 0.76
Comparison of viral hepatitis-associated hepatocellular carcinoma due to HBV and HCV - cohort from liver clinics in Pakistan. Asian Pac J Cancer Prev (2014) 0.76
Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study. Hematol Oncol Stem Cell Ther (2013) 0.76
Hospital-based cancer profile at the Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, pakistan. J Coll Physicians Surg Pak (2015) 0.76
Identifiable risk factors in hepatitis B and C. J Ayub Med Coll Abbottabad (2013) 0.75
Regional variation in identified cancer care needs of early-career oncologists in China, India, and Pakistan. Oncologist (2015) 0.75